Status:
COMPLETED
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It ma...
Detailed Description
OBJECTIVES: Primary * To determine whether germline polymorphisms (DNA) of genes involved in DNA repair (e.g., XPD, ERCC-1, and others) and angiogenesis (e.g., vascular endothelial growth factor \[V...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Available serum or plasma samples from patients with locally advanced, metastatic, or recurrent non-squamous non-small cell lung cancer
- Stage IIIB (with pleural effusion) or stage IV disease
- Enrolled on protocol ECOG-4599
- Treated with carboplatin and paclitaxel with or without bevacizumab
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy
Exclusion
Key Trial Info
Start Date :
March 15 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2009
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00900172
Start Date
March 15 2008
End Date
April 15 2009
Last Update
May 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.